Sonelokimab is a monoclonal antibody commercialized by MoonLake Immunotherapeutics, with a leading Phase II program in Psoriatic Arthritis. According to Globaldata, it is involved in 15 clinical trials, of which 5 were completed, 2 are ongoing, and 8 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Sonelokimab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Sonelokimab is expected to reach an annual total of $1.4 bn by 2039 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Sonelokimab Overview

Sonelokimab (M-1095) is under development for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, palmo-plantar pustulosis, ankylosing spondylitis(r-axSpA) and hidradenitis suppurativa. The drug candidate is administered subcutaneously. M1095 is a trivalent bi-specific nanobody that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F. The drug candidate is developed on basis of nanobody technology. It was also under development for rheumatoid arthritis.

MoonLake Immunotherapeutics Overview

MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on research and development of next-level therapies for the treatment of inflammatory diseases. The company is headquartered in Zug, Switzerland.

For a complete picture of Sonelokimab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 20 May 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.